African health systems reconstitute around domestic financing, pooled procurement and regional manufacturing
The question of who pays and who manufactures is answered, unevenly and permanently. Donor share of health expenditure settles at a structurally lower…
Claude · 2032–2042 · plausible
Prior state
The vertical donor programmes that carried HIV, immunisation and malaria delivery for two decades contracted sharply after 2025 and have not been restored. Continental institutions exist — a medicines regulator, a disease agency, a procurement platform, a manufacturing target — but national health budgets in most countries remain below the levels their governments committed to, and debt service consumes a large share of revenue.
Material change
The question of who pays and who manufactures is answered, unevenly and permanently. Donor share of health expenditure settles at a structurally lower level; domestic financing rises through earmarked levies, contributory insurance and general revenue; procurement consolidates through regional pooling that gives buyers real price leverage; and a set of African fill-finish and drug-substance facilities achieves international prequalification and supplies a measurable minority of routine childhood immunisation doses on the continent.
Why now
The transition timetables written into donor exit plans in the late 2020s expire in the early 2030s, converting a funding shock into a permanent architecture. Regulatory reliance decisions by the continental medicines regulator, phased in through the same period, are what make a continental market large enough to justify manufacturing at all. Plants commissioned in the late 2020s reach qualification — a process that reliably takes years — during this decade.
Mechanism and resistance
The binding constraint is fiscal: debt service and currency depreciation eat the revenue gains, and imported inputs cost more each time a currency slips. Established Indian manufacturers can undercut new African plants on price, so guaranteed volume commitments, not tariffs, determine whether facilities survive; several will not. Health-worker emigration, driven by the care-labour corridors described below, drains exactly the staff the new financing is meant to employ.
Consequences
Outcomes diverge sharply rather than converging: states with functioning revenue authorities and stable currencies stabilise coverage, while fragile and conflict-affected states experience measurable losses in immunisation and treatment continuity, with mortality consequences that appear in the statistics only years later. Sovereignty over supply improves while aggregate resources remain below their 2024 level — a trade that governments largely accept because the alternative was never offered. The pooled-procurement precedent spreads to diagnostics and to non-communicable-disease medicines, including the incretins described above.
End state
A structurally different health architecture: less externally financed, more regionally procured, partially self-supplied, more sovereign, and less well funded in aggregate than the system it replaced.
Observable test
External donor share of total health expenditure in named countries; share of routine immunisation doses procured from Africa-based manufacturers; the number of internationally prequalified manufacturing facilities on the continent.
Disconfirming sign
Donor financing returns to pre-2025 levels, or newly built facilities are mothballed for want of guaranteed volumes.
Themes
Public health, State capacity & development, Business & industry